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incidence
The crude incidence of endometrial carcinoma in the European
Union is 16 cases/100 000 women/year (range 13–24). The
mortality is 4–5 cases/100 000/year. The lifetime risk of
developing endometrial carcinoma is 1.7–2%, and
age-standardized incidence rates continue to rise in most
developed countries.
diagnosis
The diagnosis of endometrial carcinoma requires histopathological
confirmation. This diagnosis is made according to the WHO
pathological classification. About 80% of endometrial carcinomas
are of endometrioid type. Serous (5–10%), clear cell (1–5%),
mucinous, mixed, squamous cell, transitional cell and
undifferentiated carcinomas are other established subtypes.
Endometrial carcinosarcoma is now considered a special,
poor-prognosis subtype of endometrial carcinoma.
staging and risk assessment
Endometrial carcinoma is a surgically staged disease. The
minimal procedure should include the acquisition of peritoneal
fluid or washings, a thorough exploration of the abdominal
cavity and pelvic and para-aortic nodal areas, and a total
hysterectomy with bilateral salpingo-oophorectomy. In high-
risk cases retroperitoneal lymph node dissection and
omentectomy (for serous carcinomas) are often recommended,
though the effect of these procedures on survival is debated
[III, B].
The most widely used staging system is the one endorsed by
the Fe´de´ration Internationale de Gyne´cologie et d’Obste´trique
(FIGO) as given in Table 1.
degree of differentiation:
Cases of endometrial carcinoma should be graded according to
their degree of histological differentiation, as follows:
G1, a non-squamous, non-morula solid growth pattern
comprises £5% of the tumor;
G2, a non-squamous, non-morula solid growth pattern
comprises 5–50% of the tumor;
G3, a non-squamous, non-morula solid growth pattern
comprises >50% of the tumor.
d Notable nuclear atypia, inappropriate for the architectural grade,
raises the grade of a grade 1 or 2 tumor by one.
d Before surgery, patients should have a chest X-ray, clinical and
gynecological examination including transvaginal ultrasound,
blood counts, liver and renal function profiles. A CT scan of
the abdomen and retroperitoneal nodes may be helpful in
determining extra-uterine spread. Contrast-
enhanced dynamic MRI is the best way to assess the uterine
and locoregional pelvic extension of the disease [I, A]. There
is, however, no fully reliable method to assess an individual
patient’s risk category either pre- or intra-operatively
(frozen section). The preoperative histological diagnosis
(type and grade) based on any type of endometrial
sampling is changed at final histological evaluation in up to
25% of cases.
d Established, independent prognostic factors are FIGO surgical
stage, histological grade, depth of myometrial invasion, histological
type, tumor diameter, lymph–vascular space involvement,
endocervical stromal invasion and patient age.
d About 75% of patients present with stage I disease and can be
subdivided into three risk categories with regard to disease
relapse and survival:
(i) low risk
d stage Ia/Ib, grade 1 or 2, endometrioid histology
(ii) intermediate risk
d stage Ic, grade 1 or 2, endometrioid histology
d stage Ia/Ib, grade 3, endometrioid histology
(iii) high risk
d stage Ic, grade 3, endometrioid histology
d stage Ia or Ib or Ic, serous, clear cell, small cell or
undifferentiated histology.
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treatment plan
The type of surgery and postoperative therapy depends on the
stage and other clinicopathological risk factors.
stage I
(i) low-risk group: no adjuvant therapy.
(ii) intermediate-risk group: adjuvant pelvic radiotherapy
significantly reduces the risk of pelvic/vaginal relapses, but
has no impact on overall survival (OS) [I, A]. Within the
intermediate-risk group, in patients aged ‡60 years, with
deeply invasive G1 or G2 or superficially invasive G3
tumors, the loco-regional relapse rate is >15%, and
adjuvant radiotherapy is recommended [II, B].
(iii) high-risk group: pelvic radiotherapy is recommended in
order to increase loco-regional control. Adjuvant,
platinum-based chemotherapy gives a significantly
improved OS and progression-free survival (PFS)
compared with adjuvant radiotherapy [I, A].
stage II
d Stage IIa: treated as stage I.
d Stage IIb: extended radical hysterectomy, bilateral salpingo-
oophorectomy and lymph node dissection. Patients who had
an extrafascial hysterectomy, or who have high-risk disease
(according to definitions given for stage I) are recommended
to have adjuvant pelvic (with or without intravaginal)
radiotherapy.
d The adjuvant administration of progestational agents in low-
stage endometrial cancer does not increase survival and is not
recommended [I, A].
stages III and IV
d Maximal surgical cytoreduction is considered in patients with
good performance status [III, B].
d Patients with stage III disease solely on the basis of positive
peritoneal cyology are treated as patients with stage I or II
disease, based on the other clinicopathological data.
d Pelvic control is increased with pelvic radiotherapy.
d Cisplatin, carboplatin, anthracyclines and paclitaxel have
single-agent objective response rates.
d The combination of doxorubicin with cisplatin and paclitaxel
(with bone marrow support) significantly improves PFS and
OS compared with cisplatin and doxorubicin, but at the cost
of higher toxicity, making it less attractive in this patient
population [I, A].
d Cisplatin and doxorubicin significantly improved PFS and OS
in patients with low residual stage III and IV disease compared
with whole abdominal radiation therapy with pelvic boost [I,
A].
d Because of toxicity considerations, an alternative option may be
the combination of carboplatin and paclitaxel [III, B].
d Dosages, number of chemotherapy courses and response
evaluation as recommended for advanced-stage ovarian
cancer.
d Progestational agents, e.g. medroxyprogesterone acetate 200
mg daily, are active in steroid receptor-positive tumors
(mostly G1 and G2 lesions) [III, B].
follow-up
Most recurrences will occur within the first 3 years after
treatment, and 3- to 4-montly evaluations with history, physical
and gynecological examination are usually recommended.
Follow-up intervals of 6 months are recommended during the
fourth and fifth years, and annually thereafter. No impact on
survival of a routine follow-up strategy has been demonstrated.
However, since a significant number of relapses occur isolated
in the vagina or pelvis, early detection and possibly curative
treatment of these should be the main focus of follow-up.
Routine technical examinations such as PAP smears or imaging
studies are of unproven benefit.
note
Levels of evidence [I–V] and grades of recommendations [A–
D] as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified clinical practice by the experts and the
ESMO faculty.
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Table 1. Staging of endometrial cancer as endorsed by the Fe´de´ration
Internationale de Gyne´cologie et d’Obste´trique (FIGO)
Stage I Confined to the uterus
Ia Tumor limited to the endometrium
Ib Invasion to less than half of the myometrium
Ic Invasion to more than half of the myometrium
Stage II Extension to the uterine cervix
IIa Endocervical glandular involvement only
IIb Cervical stromal invasion
Stage III Extension beyond the uterus
IIIa Tumor invades serosa and/or adnexa, and/or positive
peritoneal cytology
IIIb Vaginal involvement
IIIc Metastasis to pelvic or para-aortic lymph nodes
Stage IV Invasion in neighboring organs or distant metastases
IVa Tumor invasion of the bladder and/or bowel mucosa
IVb Distant metastases including intra-abdominal or inguinal
lymph nodes
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